Advancing CAR-T Therapies with Real-World Clinical Data to Drive Next- Generation Development

By | 3 November 2025

Share up-to-date clinical data from the ongoing CAR-T program in T-cell leukaemia
Discuss the latest development from OneChain’s next-generation CAR-T products across hematologic malignancies and solid tumours
Explore advantages and opportunities with OneChain’s allogeneic iPSC-derived gamma delta T-cell platform

New Data